219 related articles for article (PubMed ID: 11355165)
21. Triple approach for diagnosis and grading of meningiomas: histology, morphometry of Ki-67/Feulgen stainings, and cytogenetics.
Kolles H; Niedermayer I; Schmitt C; Henn W; Feld R; Steudel WI; Zang KD; Feiden W
Acta Neurochir (Wien); 1995; 137(3-4):174-81. PubMed ID: 8789658
[TBL] [Abstract][Full Text] [Related]
22. Proteins involved in regulating bone invasion in skull base meningiomas.
Salehi F; Jalali S; Alkins R; Lee JI; Lwu S; Burrell K; Gentili F; Croul S; Zadeh G
Acta Neurochir (Wien); 2013 Mar; 155(3):421-7. PubMed ID: 23238945
[TBL] [Abstract][Full Text] [Related]
23. Differential Tumor Progression Patterns in Skull Base Versus Non-Skull Base Meningiomas: A Critical Analysis from a Long-Term Follow-Up Study and Review of Literature.
Savardekar AR; Patra DP; Bir S; Thakur JD; Mohammed N; Bollam P; Georgescu MM; Nanda A
World Neurosurg; 2018 Apr; 112():e74-e83. PubMed ID: 29258946
[TBL] [Abstract][Full Text] [Related]
24. Comparative proteomic profiles of meningioma subtypes.
Okamoto H; Li J; Vortmeyer AO; Jaffe H; Lee YS; Gläsker S; Sohn TS; Zeng W; Ikejiri B; Proescholdt MA; Mayer C; Weil RJ; Oldfield EH; Zhuang Z
Cancer Res; 2006 Oct; 66(20):10199-204. PubMed ID: 17047085
[TBL] [Abstract][Full Text] [Related]
25. Histological classification and molecular genetics of meningiomas.
Riemenschneider MJ; Perry A; Reifenberger G
Lancet Neurol; 2006 Dec; 5(12):1045-54. PubMed ID: 17110285
[TBL] [Abstract][Full Text] [Related]
26. SMO mutation status defines a distinct and frequent molecular subgroup in olfactory groove meningiomas.
Boetto J; Bielle F; Sanson M; Peyre M; Kalamarides M
Neuro Oncol; 2017 Mar; 19(3):345-351. PubMed ID: 28082415
[TBL] [Abstract][Full Text] [Related]
27. Histopathological parameters with Ki-67 and bcl-2 in the prognosis of meningiomas according to WHO 2000 classification.
Uzüm N; Ataoğlu GA
Tumori; 2008; 94(3):389-97. PubMed ID: 18705408
[TBL] [Abstract][Full Text] [Related]
28. Risk group-adapted adjuvant radiotherapy for WHO grade I and II skull base meningioma.
Park S; Cha YJ; Suh SH; Lee IJ; Lee KS; Hong CK; Kim JW
J Cancer Res Clin Oncol; 2019 May; 145(5):1351-1360. PubMed ID: 30953136
[TBL] [Abstract][Full Text] [Related]
29. Malignant progression to anaplastic meningioma: Neuropathology, molecular pathology, and experimental models.
Cimino PJ
Exp Mol Pathol; 2015 Oct; 99(2):354-9. PubMed ID: 26302177
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in anterior skull base meningiomas.
Ciocan LM; Dănăilă L; Stănculescu DE; Neamţu SD; Mateescu GO; Stanca L
Rom J Morphol Embryol; 2014; 55(3 Suppl):1063-9. PubMed ID: 25607386
[TBL] [Abstract][Full Text] [Related]
31. The histopathological spectrum of human meningiomas.
Backer-Grøndahl T; Moen BH; Torp SH
Int J Clin Exp Pathol; 2012; 5(3):231-42. PubMed ID: 22558478
[TBL] [Abstract][Full Text] [Related]
32. Nucleolar organizer regions in meningiomas. Correlation with histopathologic malignancy grading, DNA cytometry and clinical outcome.
Plate KH; Ruschoff J; Mennel HD
Anal Quant Cytol Histol; 1990 Dec; 12(6):429-38. PubMed ID: 2078265
[TBL] [Abstract][Full Text] [Related]
33. Clear-cell meningioma of the anterior cranial fossa. Case report and review of the literature.
Pizzoni C; Sarandria C; Pierangeli E
J Neurosurg Sci; 2009 Sep; 53(3):113-7. PubMed ID: 20075823
[TBL] [Abstract][Full Text] [Related]
34. Pathology of meningiomas.
Solomon DA; Pekmezci M
Handb Clin Neurol; 2020; 169():87-99. PubMed ID: 32553300
[TBL] [Abstract][Full Text] [Related]
35. Chordoid Meningioma - A Case Report: Clinicopathological Features and Differential Diagnosis of an Uncommon Tumor.
Özer H; Tuncer E; Saray G; Gürelik M; Öztoprak İ; Eğilmez R
Turk Patoloji Derg; 2016; 32(2):130-4. PubMed ID: 24715552
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical comparison of chordoma with chondrosarcoma, myxopapillary ependymoma, and chordoid meningioma.
Cho HY; Lee M; Takei H; Dancer J; Ro JY; Zhai QJ
Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):131-8. PubMed ID: 19521276
[TBL] [Abstract][Full Text] [Related]
37. Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas.
Kim D; Niemierko A; Hwang WL; Stemmer-Rachamimov AO; Curry WT; Barker FG; Martuza RL; Oh KS; Loeffler JS; Shih HA
J Neurosurg; 2018 Apr; 128(4):1123-1132. PubMed ID: 28621619
[TBL] [Abstract][Full Text] [Related]
38. Osteopontin predicts the behaviour of atypical meningioma.
Lin CK; Tsai WC; Lin YC; Hueng DY
Histopathology; 2012 Jan; 60(2):320-5. PubMed ID: 22211290
[TBL] [Abstract][Full Text] [Related]
39. Assessment of tumor blood flow and its correlation with histopathologic features in skull base meningiomas and schwannomas by using pseudo-continuous arterial spin labeling images.
Yamamoto T; Takeuchi H; Kinoshita K; Kosaka N; Kimura H
Eur J Radiol; 2014 May; 83(5):817-23. PubMed ID: 24581592
[TBL] [Abstract][Full Text] [Related]
40. Relationship between malignant subtypes of meningioma and clinical outcome.
Ko KW; Nam DH; Kong DS; Lee JI; Park K; Kim JH
J Clin Neurosci; 2007 Aug; 14(8):747-53. PubMed ID: 17499508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
